CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
ASP8082 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04448561
NCT04448561Phase 1Completed
CompareCT.gov

A Phase 1 Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 With a Single Dose of Morphine in Recreational Opioid Using Participants

Astellas Pharma Global Development, Inc.·interventional·Posted Jun 26, 2020·Updated Nov 21, 2024

In Brief

A Phase 1 clinical trial evaluating ASP8082, morphine, and 1 other intervention for Opioid Use Disorder. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The primary purpose of this study was to assess the safety and tolerability of multiple doses of ASP8062 or placebo alone and in combination with a single dose of morphine. This study also assessed the potential for pharmacokinetic interaction between ASP8062 and morphine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid Use Disorder
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedJun 26, 2020
Enrollment StartJun 30, 2020
Primary CompletionSep 11, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.0 years ago

Interventions

ASP8082drug

oral

morphinedrug

oral

Placebodrug

oral